ClinicalTrials.gg
RecruitingNCT06715007Athena-cSVDUpdated Mar 28, 2025

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

An observational study in Stroke, Ischemic, Small Vessel Cerebrovascular Disease and White Matter Hyperintensity, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
121st of 188
300 · median 625
Started
2024
with 102 others
Observational
188 of 754
108 open now
Primary completion
2025-12
later than 78 of 399 live
Registered
409th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 121st largest by planned enrollment of the 188 observational ones that give a count, is one of 103 that started in 2024, is one of 188 observational ones, reaches primary completion later than 78 of the 399 other live ones, and was the 409th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

376 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

Read the detailed description

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. It refers to a group of pathological processes with various etiologies that affect the small arteries, arterioles, venules, and capillaries of the brain. On neuroimaging, notably on magnetic resonance imaging (MRI), SVD has several visible signs, including recent small subcortical infarcts (i.e symptomatic cSVD in our study), lacunes of presumed vascular origin; white matter hyperintensities (WMH), perivascular spaces, cerebral microbleeds, cerebral microinfarcts and brain atrophy. SVD causes about a quarter of ischaemic strokes, is the main cause of vascular dementia, often occurs with Alzheimer's disease, contributing to about 50% of dementias worldwide. Although previous studies recommend BP control and antiplatelet therapy in symptomatic cSVD, secondary prevention strategies are mostly inferred from studies of ischemic stroke in general, the majority of which did not specifically investigate patients with symptomatic cSVD. In addition, long term dual antiplatelet therapy using clopidogrel and aspirin was shown to increase the risk of hemorrhage stroke in symptomatic cSVD, without any decrease in recurrent ischemic stroke.

Endothelial dysfunction plays an important part in cSVD. In addition to mild antiplatelet effects through the increase of cyclic adenosine monophosphate (cAMP), the phosphodiesterase (PDE) 3' inhibitor cilostazol is shown to be endothelial protective by several pathways, such as activation of endothelial nitric oxide (NO) synthase (NOS), regulation of endothelin-1. Isosorbide mononitrate (ISMN) is a NO donor, by augmenting the NO-cyclic guanosinemonophosphate phosphodiesterase-inhibitor pathway. Recent trial showed that the combined use of ISMN plus cilostazol was well tolerated and safe, and may reduce recurrent stroke and cognitive impairment after lacunar stroke.

Brain and retina possess numerous anatomical and functional similarities. Retinal capillary microvessels revealed by optical coherence tomography angiography (OCTA) have been found to be related to brain microvessels, reflecting the burden of cSVD. Retinal perfusion is also linked with cognitive function.

This cohort study will prospectively evaluate the effect of different antiplatelet agents on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

03

Conditions studied

  • Stroke, Ischemic
  • Small Vessel Cerebrovascular Disease
  • White Matter Hyperintensity

Keywords

  • cerebral small vessel disease
  • White Matter Hyperintensity
  • recent small subcortical infarcts
  • Endothelial dysfunction
  • cilostazol
04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with a recent small subcortical infarct that occurred within 3 weeks prior to randomization, or patient with whiter matter hyperintensities with a 2-3 grading on Fazekas scale will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 30 years and ≤ 79 years.
  2. A recent small subcortical infarct that occurred within 3 weeks prior to randomization; or patient with whiter matter hyperintensities with a 2-3 grading on Fazekas scale.
  3. Absence of signs or symptoms of cortical dysfunction, such as aphasia, apraxia, agnosia, agraphia, homonymous visual field defect.
  4. Modified Rankin score of ≤ 4.
  5. In the absence of any other pathology in the parent artery at the site of the origin of the penetrating artery (focal atheroma, parent vessel dissection, vasculitis, vasospasm, and so on).
  1. No ipsilateral cervical carotid stenosis (≥30%) by brain high resolution magnetic resonance imaging (HRMRI) or computed tomography angioplasty (CTA) or (magnetic resonance angioplasty) MRA and cervical artery ultrasound, if qualifying event is hemispheric. No vertebra artery stenosis (≥30%) by brain HRMRI or CTA or MRA and cervical artery ultrasound, if the lesion is in the territory of posterior circulation.
  1. No major-risk cardioembolic sources requiring anticoagulation or other specific therapy.
  1. Patient agrees with follow-up visits and is available by phone. 10. Patient understands the purpose and requirements of the study, can make him/herself understood, and has signed .

Exclusion criteria

Exclusion criteria:

  1. Intracranial aneurysms that need surgical treatment. Other significant active neurological illness e.g seizures, multiple sclerosis, intracranial tumor (except meningioma) or any intracranial vascular malformation.
  2. Active cardiac disease (atrial fibrillation, myocardial infarct in last six months, active angina, symptomatic cardiac failure).
  3. History of any intracranial hemorrhage (parenchymal, subarachnoid, subdural, epidural).
  4. Known allergy or to aspirin, clopidogrel, cilostazol, isosorbide mononitrate or statin.
  5. Active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, \< 100,000, hematocrit \< 30, (INR) > 1.5, clotting factor abnormality that increases the risk of bleeding, current alcohol or substance abuse, uncontrolled severe hypertension (systolic pressure > 180 mm Hg or diastolic pressure > 115 mm Hg), severe liver impairment ( [AST] or alanine transaminase [ALT] > 3 x normal, cirrhosis), creatine kinase > 5 times the (ULN) at final screening, severe renal dysfunction, defined as an estimated (eGFR) \< 20mL/min/1.73 square meter at final screening.
  6. Major surgery (including open femoral, aortic, cardiac or carotid surgery) within previous 30 days or planned in the 1 year after enrollment.
  7. Dementia or psychiatric problem that prevents the patient from relevant evaluation or follow-up reliably.
  8. Co-morbid conditions that may limit survival to less than 1 year.
  9. Currently breastfeeding, pregnancy, planning to become pregnant and unwilling to use for the duration of this study
  10. Unable to tolerate, or contraindication to, MRI.
  11. Enrollment in another study that would conflict with the current study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with recent small subcortical infarct

    Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

    Drug: Clopidogrel · Drug: Aspirin · Drug: Cilostazol + Isosorbide Mononitrate

  • Patients with Whiter matter changes

    White matter hyperintensities with a 2-3 grading on Fazekas scale will be recruited. Patient in this group will receive antiplatelet treatment (e.g. Aspirin, Clopidogrel, or Cilostazol),

    Drug: Clopidogrel · Drug: Aspirin · Drug: Cilostazol + Isosorbide Mononitrate

Interventions

06

What researchers measure

Primary outcomes

  1. the impact of different antiplatelet agents on retinal vasculature.

    retinal vasculature will be assessed by optical coherence tomography and optical coherence tomography angiography.

    Time frame: 6 months follow up

Secondary outcomes

  1. systemic or intracranial bleeding

    Time frame: systemic or intracranial bleeding will be assessed during 6 month follow-up.

  2. occurrence of ischemic stroke or transient ischemic attack

    Time frame: during 6 month follow-up

  3. Neurological function

    Neurological function will be assessed by NIHSS (National institute of health stroke scale)

    Time frame: Neurological function will be assessed at baseline, 1 week, 3 months and 6-month after recruitment.

  4. Brain MRI (magnetic resonance imaging)

    Brain MRI to evaluate whiter matter hyperintensities.

    Time frame: Brain MR will be performed at baseline and at 6 months after recruitment

  5. Cognitive function

    Montreal cognitive assessment (MoCA) will be used.

    Time frame: MoCA will be assessed at baseline and at 3 and 6 months after recruitment.

  6. modified Rankin Scale (mRS) score

    Time frame: modified Rankin Scale (mRS) score will be assessed at baseline and at 3 and 6 months after recruitment.

  7. Barthel index for activities of daily living

    Barthel index for activities of daily living is an ordinal scale which measures a person's ablility to complete activities of of daily living.

    Time frame: Barthel index will be assessed at baseline, 3 and 6 months after recruitment.

  8. Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)

    MDS-UPDRS is scale to evaluate various aspects Parkinson's disease or Parkinsonism including non-motor and motor experiences of daily living and motor complications. Small vessel diseases may cause Parkinsonism, we thus use this scale in our study.

    Time frame: UPDRS score will be evaluated at baseline and 3, 6 months after recruitment.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 12 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 4, 2024
StartActual
Dec 20, 2024
Primary completionEst.
Dec 20, 2025
CompletionEst.
Jan 20, 2026
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06715007
Responsible party
Wang Zhaolu (Professor, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Dec 4, 2024
Start date
Dec 20, 2024
Primary completion
Dec 20, 2025 (estimated)
Completion
Jan 20, 2026 (estimated)
Last update
Mar 28, 2025

Study contacts

Zhaolu Wang, MD
Contact
wangzhaolu123@163.com
+86 18100613663
Xinyu Chen
Contact
njmuchenxinyu@163.com
zhaolu wang, MD
study director · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion